• Read more about Determination of Immune Evasion Phenotypes of HNSCC

The programmed death (PD-1/PD-L1) pathway is the focus of immunotherapeutic checkpoint inhibition for the control of head and neck squamous cell carcinoma (HNSCC). 

• Read more about Detection of PD-L1 expression on HNSCC cells

The Programmed Death (PD) pathway, involving receptor PD-1 on T-cells and ligand PD-L1 on tumor cells is an important immunotherapeutic checkpoint to inhibit in the control of head and neck squamous cell carcinoma (HNSCC).

• Read more about PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression

PD-L1 expression can be constitutive and inducible. Constitutive expression is dependent upon cell genomics. Deleterious gene mutations influence cell signaling with downstream effects on PD-L1 expression levels. Inducible PD-L1 expression is dependent upon exposure of cells to IFNγ, TNFα, IL-1α, and IL-1β via TLRs or IFN receptors in the ERK and IFNγ signaling networks (1,4).

• Read more about Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

Background: MDS is a marrow stem cell disorder with limited treatments. Due to outcome heterogeneity of MDS, it is imperative to identify prognostic tools for patients in clinical trials. Rigosertib (RIG) is a RAS-mimetic that inhibits cellular signaling pathways by binding to the RAS-binding Domain found in RAS effector proteins.

• Read more about A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patient with AML and MDS

Background: Hypomethylating agents (HMAs) (e.g., azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used in the treatment of patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

• Read more about A Genomic Rule Predicting HMA Treatment Response in MDS Identified By Protein Network Mapping and Validated By Clinical Trial Simulation

Background: Hypomethyating agents (HMAs) for the treatment of the myelodysplastic syndromes (MDS) fail to achieve clinical improvement in nearly 60% of patients.

• Read more about A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A beat AML Project Study

Background: Data from a small clinical trial of venetoclax in acute myeloid leukemia (AML) recently supported FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients who are ineligible for high-dose induction chemotherapy.

• Read more about Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances

Background: Multiple myeloma (MM) is an incurable heterogeneous hematological malignancy in which immune suppression and complex biology affect the disease and its response to treatment.

• Read more about Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

Although the majority of MDS patients fail to achieve clinical improvement to approved therapies, some patients benefit from treatment. Predicting patient response prior to therapy would improve treatment effectiveness, avoid treatment-related adverse events and reduce healthcare costs. Three separate cohorts of MDS patients were used to simulate drug response to lenalidomide alone, hypomethylating agent (HMA) alone, or HMA plus lenalidomide.

• Read more about Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models

Interaction of the programmed death-1 (PD-1) co-receptor on T cells with the programmed death-ligand 1 (PD-L1) on tumor cells can lead to immunosuppression, a key event in the pathogenesis of many tumors.